Studien & Zertifizierung

Biofeedback significantly reduced headache frequency and severity vs. waitlist control. No significant difference vs. pharmacotherapy or CBT, establishing clinical equivalence. Synergistic benefit when combined with medication.

Mishra et al. ScienceDirect, 2025 (SR/MA, 558 participants). Nestoriuc et al. Appl Psychophysiol Biofeedback, 2008.

Consistent efficacy as complementary therapy across diverse chronic pain conditions, with significant reductions in pain intensity and quality of life improvements. EMG biofeedback particularly effective for musculoskeletal pain; HRV biofeedback for central sensitization syndromes.

Constans et al. ScienceDirect/PMC, 2025 (PRISMA SR, 2014-2024). Lazaridou et al. 2023 (RCT, chronic low back pain).

Significant positive effects on: hypertension and cardiovascular prognosis, inflammatory state, asthma management, depression and anxiety, sleep disturbances, and cognitive performance. No adverse effects reported.

Lalanza et al. Appl Psychophysiol Biofeedback, 2023 (PRISMA SR, 143 studies). SR Diabetes & Metabolic Syndrome, 2024 (29 articles).

Statistically superior to waitlist control. Multi-modal biofeedback (combined HRV + GSR + EEG) was most effective, suggesting broader physiological coverage increases therapeutic efficacy. Anxiety was the most commonly treated condition (68.3% of studies). A 4-week RCT (n=52) showed significant improvements in anxiety, depression, and insomnia (p<0.05).

Tolin et al. Adv Exp Med Biol 2020 (SR). Wang et al. Appl Psychophysiol Biofeedback 49(1):71–83, 2024 (RCT, n=52). Guidi et al. PubMed PMID: 33792548.

Large effect sizes in MDD studies: Hedges' g = 1.050 (between-group). HRV biofeedback: meta-analyses report g=0.38–0.48; 34% superior to treatment as usual; remote HRVB effective (18 studies, N=1,352). Neurofeedback outperformed rTMS and tDCS in enhancing cognitive function. Dose-response relationship confirmed.

Pizzoli et al. Scientific Reports 2021 (14 RCTs, g=0.38). Donnelly et al. Acta Biomedica 2023 (9 RCTs, g=0.478). Springer Appl Psychophysiol Biofeedback 2025 (18 studies, remote HRVB). Fernandez-Alvarez et al. Psychological Medicine 2022.

Neurofeedback vs. passive controls: moderate-to-large effect (SMD = 0.64; p = 0.002). Neurophysiological changes (alpha rhythm normalization) correlated with clinical improvement. Meaningful adjunct given 39-72% non-response to standard psychotherapy in military populations.

Voigt et al. Frontiers in Psychiatry, 2024 (SR/MA, 17 RCTs, 628 patients). Askovic et al. Eur J Psychotraumatology, 2023.

Clear, consistent evidence of benefit as adjunctive therapy for urinary incontinence following prostatectomy and fecal incontinence. Medicare-reimbursable in the U.S. (NCD 30.1).

Kondo et al. VA Evidence Synthesis Program, 2019 (Evidence Map, 16 systematic reviews). PMC6854143.

Neurofeedback improves reaction time, cognitive performance, and emotional regulation across diverse sports (archery, soccer, volleyball, judo). Biofeedback aligns with stress resilience; neurofeedback with cognitive-motor optimization. Optimal protocol: 4-10 weeks, 2-3 sessions/week.

Tosti et al. Brain Sciences, 2024 (PRISMA SR, 24 studies). Frontiers in Psychology, 2025 (Bayesian MA).

HRV biofeedback in breast cancer survivors: significant increase in low-frequency HRV (p = 0.027), long-lasting sleep quality improvement, and psychological well-being maintained at 6-month follow-up.

Three-arm longitudinal RCT, 60 post-treatment breast cancer patients, UK, 2025.

Cognitive (MoCA), motor (Fugl-Meyer), psychological (perceived stress), and autonomic function all improved at 3 and 6 months. Benefits became more pronounced over time.

RCT, 62 ischemic stroke patients. ScienceDirect, 2024.

89% of included studies reported positive outcomes for occupational stress reduction. Breathing-based biofeedback targeting HRV was particularly effective. Mobile app-directed and short-session interventions showed particular promise for resilience building.

PubMed, 2025. PMID: 40939175 (PRISMA, 2012-2024).

EEG neurofeedback combined with standard pharmacotherapy significantly improved both positive and negative symptoms of schizophrenia compared to medication alone.

Duan et al. Frontiers in Psychiatry, 2025 (SR/MA, 14 studies, 1,371 participants).

EEG-based neurofeedback shows efficacy as an adjunct for binge-eating disorder in systematic reviews and meta-analyses of RCTs. Pilot RCTs of EEG neurofeedback in adults with binge eating and overweight reduced objective binge episodes and eating-disorder psychopathology; some participants maintained abstinence at follow-up. Digital interventions including biofeedback in obesity management show modest effects (e.g. waist circumference). Position as complement to multidisciplinary approaches, not as replacement.

SR/MA neurofeedback for binge eating, ScienceDirect. Neurotherapeutics 2021 (pilot RCT, N=39; PMC9130382). Nutrients 2025, SR/MA of e-health/m-health interventions in obesity (PubMed 40647304).

Short PRISMA systematic reviews and studies of biofeedback and neurofeedback in smokers suggest that training may modulate craving and smoking-related brain plasticity. The Cochrane review on feedback about the effects of smoking on the body found no clear evidence that such feedback increases cessation rates. The literature supports the use of biofeedback as complementary support during the cessation process, not as a guarantee of quitting.

The effect of biofeedback on smoking cessation–a systematic short review, PMC8825623 (2021). Advances in biofeedback and neurofeedback studies on smoking, ScienceDirect 2020. Frontiers in Behavioral Neuroscience 2023 (biofeedback+neurofeedback and cessation status). Cochrane CD004705.

HRV biofeedback in a pilot (n=28) showed medium-large effect on fatigue and superior cognitive outcomes vs. graded exercise. Position as complement to multidisciplinary approaches.

Vos-Vromans et al. J Psychosomatic Research 2016. doi:10.1016/j.jpsychores.2016.12.001

A randomized trial of biofeedback-assisted relaxation in mild asthma patients (N=16) showed reduced asthma severity, lower bronchodilator use, improved pulmonary function, and immune markers (reduced neutrophils and basophils). Evidence for allergic desensitization per se (e.g. IgE-mediated) comes from immunotherapy, not biofeedback. Biofeedback may be considered as complementary support in the management of allergic reactivity and stress-mediated components, not as a replacement for established treatment.

Asthma Severity, Psychophysiological Indicators of Arousal, and Immune Function in Asthma Patients Undergoing Biofeedback-Assisted Relaxation, Appl Psychophysiol Biofeedback 2000 (Springer).